Related Experiment Video
Updated: Jun 12, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Abacavir and cardiovascular risk: reviewing the evidence
Dominique Costagliola1, Sylvie Lang, Murielle Mary-Krause
1UMR S 943, UPMC Univ-Paris 6, Paris, F75013, France. dominique.costagliola@upmc.fr
Abstract:
Since the presentation of the D:A:D study results at the Conference on Retroviruses and Opportunistic Infections in February 2008, 10 studies have explored the association between exposure to abacavir and the risk of myocardial infarction. Among the five larger studies, three conclude that there is an association and two that the association is not robust. Based on these studies, it is impossible to refute or confirm a causal relationship, as it is not possible to exclude remaining confounding (smoking in two of the studies, kidney function in two of the studies, cocaine and/or intravenous drug use) and selection bias in studies that report a robust association. In addition, no convincing mechanism has been described.
Related Concept Videos
Cardiovascular Drugs: Classification based on Therapeutic Indications
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
